Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495985 · ClinicalTrials.gov registry record
CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer
A clinical trial of Thyroid Cancer, sponsored by The Cleveland Clinic.
- Active
- Registry status
- 39
- Enrollment target
- 1
- Study location
NCT04495985 is a study of Thyroid Cancer that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 39 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04495985, a study of Thyroid Cancer, is active but no longer recruiting, sponsored by The Cleveland Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Radioactive iodine (RAI) is a radioisotope used to ablate thyroid gland remnant after thyroidectomy in patients diagnosed with differentiated thyroid carcinoma (DTC). A whole body scan (WBS) is performed to not only evaluate for iodine uptake by the native thyroid tissue but also to observe for uptake in other areas of the body, which could be physiological or indicative of iodide-avid metastases. Research has shown a correlation between breast cancer and thyroid cancer. Patients with DTC have been found to have elevated levels of serum prolactin, which could lead to mammary gland dysfunction. In patients with DTC undergoing RAI scanning or therapy, it has been previously observed that patients prepared by thyroid hormone withdrawal have significantly higher breast uptake on whole body scan compared to those prepared by rh-TSH. Considering the impact of prolactin on breast tissue, this study aims to correlate these findings with the lab values and the method of preparation. Accordingly, the research question is as follows: does the method of WBS preparation impact prolactin levels and how does that correlate with breast uptake in patients with DTC undergoing RAI WBS?
Conditions Studied
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04495985
The ClinicalTrials.gov registry entry for NCT04495985 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (86% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04495985 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04495985 about?
NCT04495985 is a clinical study titled "CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer". Radioactive iodine (RAI) is a radioisotope used to ablate thyroid gland remnant after thyroidectomy in patients diagnosed with differentiated thyroid carcinoma (DTC). A whole body scan (WBS) is performed to not only evaluate for iodine uptake by the native thyroid tissue but also to observe for upta...
What is the current status of trial NCT04495985?
This trial is currently active not recruiting. The enrollment target is 39 participants. The study started on 2020-07-14. Estimated completion is 2026-12.
What conditions does trial NCT04495985 study?
This clinical trial studies the following conditions: Thyroid Cancer.
Who is sponsoring clinical trial NCT04495985?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04495985 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.